API
Backed by our strong R&D team and state-of-the-art facilities, we, at Raghav Life Science, have developed commercially viable processes for generic APIs and intermediates for our global partners. We offer high-quality generic drugs at competitive costs by integrating our experience, skills, and technology-driven operations.
To reach high standards of operational efficiency and consistent production, our manufacturing processes are built around quality control and assurance, supply chain management, regulatory and project management.
Our manufacturing facilities are designed to handle a wide range of complex chemistries and operating conditions allowing our partners to convert their concepts to bulk drug API production.
-
Competitive global prices with quality and consistent production.
-
Globally recognized, WHO GMP certified manufacturing plant
-
ISO 9001:2015 Certified for R&D Lab
-
Reliable customer support through knowledge transfer and documentation support.
APIsList
We at Raghava Life Science discover solutions that reduce costs and increase speed to market. If you have questions, our experienced R&D team is ready to talk with you to help you accelerate your most pressing commercial API manufacturing project. You can call us at 111
| API Name | CAS Number | Specifications | Therapeutic Category | Status |
|---|---|---|---|---|
| Lacosamide | 175481-36-4 | EP | Anticonvulsant | Commercialized. DMF is available |
| Favipiravir | 259793-96-9 | cIn-house (ICH) | Antiviral | Commercialized. DMF is available |
| Bilastine | 202189-78-4 | In-house (ICH) | Antihistamine | Commercialized. DMF is available |
| Levetiracetam | 102767-28-2 | USP/EP/IP | Anticonvulsant | Commercialized. ODMF work is in progress |
| Vildagliptin | 274901-16-5 | In-house (ICH) | Antidiabetic | Commercialized. ODMF work is in progress |
| Linagliptin | 668270-12-0 | In-house (ICH) | Antidiabetic | Commercialized. ODMF work is in progress |
| Rivaroxaban | 366789-02-8 | In-house (ICH) | Anticoagulant | Commercialized. ODMF work is in progress |
| Molnupiravir | 2349386-89-4 | In-house (ICH) | Antiviral | Under Commercialisation |
APIsUNDER DEVELOPMENT
| API Name | CAS Number | Specifications | Therapeutic Category | Status |
|---|---|---|---|---|
| Apixaban | 503612-47-3 | In-house (ICH) | Anticoagulant | Optimisation under progress |
| Empagliflozin | 864070-44-0 | In-house (ICH) | Antidiabetic | Optimisation under progress |
| Dapagliflozin | 960404-48-2 | In-house (ICH) | Antidiabetic | Optimisation under progress |
| Amlodipine Besylate |
88150-42-9 | In-house (ICH) | Antihypertension | Under Commercialisation |
| Ibuprofen | 15687-27-1 | In-house (ICH) | NSAID | Optimisation under progress |
| Sitagliptin | 486460-32-6 | In-house (ICH) | Antidiabetic | Under development |
| Oseltamivir | 196618-13-0 | In-house (ICH) | Antiviral | Under development |
| Losartan | 114798-26-4 | In-house (ICH) | Angiotensin receptor blockers | Under development |
| Telmisartan | 144701-48-4 | In-house (ICH) | Angiotensin II receptor antagonists | Under development |
Contact us
Fully dedicated
in your service.
To reach high standards of operational efficiency and consistent production, our manufacturing processes are built around quality control and assurance, supply chain management, regulatory and project management.
GEt in touch
-
11-8-21, plot no - 15, gandhi
nagar, begumpet, Hyderabad
